«Beginning with our first anti-HIV drug, Viread, approved in 2001, and with the
subsequent launches of Emtriva, Truvada, and most recently Atripla, all of which are
dosed once
daily with or without food, Gilead has been front and center in developing once -
daily combination antiretroviral therapy,» Bischofberger says.